Macrogenics Intrinsic Value Calculator – MACROGENICS Reports Q2 Earnings – Total Revenue Down 49.5% YOY

August 24, 2023

🌥️Earnings Overview

On August 9 2023, MACROGENICS ($NASDAQ:MGNX) reported their FY2023 Q2 earnings results showing a total revenue of USD 13.1 million – a decrease of 49.5% year-over-year. Net income for the quarter was significantly improved from the prior year’s -41.3 million, coming in at USD 57.5 million.

Analysis – Macrogenics Intrinsic Value Calculator

GoodWhale is a great tool to analyze MACROGENICS‘s financials. According to our proprietary Valuation Line, the fair value of MACROGENICS share is around $20.9. It means that the current price of MACROGENICS stock, which is $5.0, is undervalued by 76.1%. It provides an opportunity for investors to buy the stock at a discounted price and make a profit in the future. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • MACROGENICS_Reports_Q2_Earnings_-_Total_Revenue_Down_49.5_YOY”>Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Macrogenics. More…

    Total Revenues Net Income Net Margin
    150.54 7.45 4.9%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Macrogenics. More…

    Operations Investing Financing
    4.98 -19.22 101.54
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Macrogenics. More…

    Total Assets Total Liabilities Book Value Per Share
    305.65 134.11 2.77
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Macrogenics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    28.4% 4.8%
    FCF Margin ROE ROA
    2.1% 3.2% 1.5%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    Macrogenics’ proprietary technology involves the use of engineered human antibodies to target disease-causing proteins. The company has four product candidates in clinical development for the treatment of various cancers and autoimmune diseases. Macrogenics’ competitors in the antibody therapeutics market include Nuvation Bio, Inc., Adocia, and Tonix Pharmaceuticals Holding Corp.

    – Nuvation Bio Inc ($NYSE:NUVB)

    Nuvation Bio Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for the treatment of cancer and other serious diseases. Its lead product candidate is rovalpituzumab tesirine, an antibody-drug conjugate (ADC) targeting delta-like protein 3 (DLL3), which is in Phase II clinical development for the treatment of small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), mesothelioma, and pancreatic cancer. The Company is also developing NB-01, a DLL3-targeted ADC for the treatment of SCLC and NSCLC, which is in preclinical development.

    – Adocia ($LTS:0QAI)

    Adocia is a company that produces medicines and treatments for diabetes. The company has a market cap of 30.91M as of 2022 and a Return on Equity of 33.93%. Adocia’s products include insulin, GLP-1 analogs, and SGLT2 inhibitors. The company’s products are used to treat type 1 and type 2 diabetes.

    – Tonix Pharmaceuticals Holding Corp ($NASDAQ:TNXP)

    Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company. The company’s focus is on discovering, licensing, acquiring and developing small molecule drugs, biologics and natural product drugs to treat serious neurological, psychiatric and immunologic disorders.


    Macrogenics reported their FY2023 Q2 earnings results with total revenue of USD 13.1 million, a decrease of 49.5% compared to the same period last year. Net income for the quarter was reported to be USD 57.5 million, a significant improvement from the prior year’s -41.3 million. Investors should consider the fact that Macrogenics has been able to increase their net income despite a substantial decrease in their revenue for this quarter, and this could be an indication of a strong financial position. Going forward, investors should analyze Macrogenics’ cash flow performance, corporate strategies, and competitive landscape to gain insight into future prospects.

    Recent Posts

    Leave a Comment